# A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

> **NCT01178086** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 681 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01178086
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-22
- **Primary completion:** 2015-06-30
- **Final completion:** 2015-06-30
- **Target enrollment:** 681 (ACTUAL)
- **Last updated:** 2018-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178086, "A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01178086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*